Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
- Conditions
- Breast Cancer
- Registration Number
- NCT03123263
- Lead Sponsor
- Texas Tech University Health Sciences Center, El Paso
- Brief Summary
This study retrospectively looks at changes in Echocardiographic parameters while using transtuzumab
- Detailed Description
Transtuzumab based chemo-immunotherapy is commonly administered to patients diagnosed with early stage HER-2 expressing breast cancer, because it decreases the risk of relapse.
Transtuzumab affects cardiac function and potential benefits in decreasing cancer recurrence have to be balanced against short and long term toxicity.
We have previously identified a high prevalence of metabolic syndrome and type II diabetes mellitus in our patients with breast cancer. These patients may be particularly susceptible to cardiotoxic effects of transtuzumab based therapy.
Aim of this study is to assess the changes in the cardiac function of women who are undergoing transtuzumab based therapy for early stage breast cancer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 60
- Stage 1,2,3 breast cancer
- Her2+
- Stage 4 cancer
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method LVEF Baseline (prior to therapy), at 3-6 months (mid-therapy), and at 1 year (end of therapy) LV ejection fraction
- Secondary Outcome Measures
Name Time Method Number of Participants Hospitalized for Cardiac Issues. 1 year any hospitalization for cardiac issues
Trial Locations
- Locations (1)
Ttuhsc
🇺🇸El Paso, Texas, United States